HPA050039

antibody from Atlas Antibodies

Targeting: SERPINE1 PAI, PAI1, PLANH1

Immunocytochemistry (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

HPA050039

Provider

Atlas Antibodies

Proper citation

Atlas Antibodies Cat#HPA050039, RRID:AB_2680997

Product name

Anti-SERPINE1

Antibody type

Polyclonal

Description

Polyclonal Antibody against Human SERPINE1, Gene description: serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1, Alternative Gene Names: PAI, PAI1, PLANH1, Validated applications: ICC, IHC, Uniprot ID: P05121, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

100 µl

Concentration

0.05 mg/ml

Storage

Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Handling

The antibody solution should be gently mixed before use.

References

Submitted references

PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity

Furuya H, Sasaki Y, Chen R, Peres R, Hokutan K, Murakami K, Kim N, Chan O, Pagano I, Dyrskjøt L, Jensen J, Malmstrom P, Segersten U, Sun Y, Arab A, Goodarzi H, Goodison S, Rosser C
Scientific Reports 2022;12(1)

---

Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma Tumors

Wang X, Bustos M, Zhang X, Ramos R, Tan C, Iida Y, Chang S, Salomon M, Tran K, Gentry R, Kravtsova-Ivantsiv Y, Kelly D, Mills G, Ciechanover A, Mao Y, Hoon D
Cancers 2020;12(5):1081

---

Prognostic Significance of Lymphocyte Infiltration and a Stromal Immunostaining of a Bladder Cancer Associated Diagnostic Panel in Urothelial Carcinoma

Furuya H, Chan O, Hokutan K, Tsukikawa Y, Chee K, Kozai L, Chan K, Dai Y, Wong R, Rosser C
Diagnostics 2019;10(1):14

---

Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients

Chan O, Furuya H, Pagano I, Shimizu Y, Hokutan K, Dyrskjøt L, Jensen J, Malmstrom P, Segersten U, Janku F, Rosser C
Oncotarget 2017;8(59):99707-99721

---

Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature

Zhang G, Gomes-Giacoia E, Dai Y, Lawton A, Miyake M, Furuya H, Goodison S, Rosser C
Diagnostic Pathology 2014;9(1)